Dear Sir/Madam.

We would like to thank Reviewer 1, Science editor and Company editor-in-chief for

the thorough and helpful review and guidelines for improvement of our manuscript.

We have attempted to take the very thoughtful comments into account. Below is a

point-by-point summary of the changes.

Reviewer's comments:

This is a narrative review of the literature on the possibilities of using the combination

of electrochemotherapy and immunotherapy in liver tumors. The authors report, in a

clear and structured way, the results of some of their studies and other experiences in

the literature. The possibility of obtaining an immunostimulating effect in these

tumors, through the use of electrochemotherapy, together with other possible

advanced therapeutic integrations based on the latter, are illustrated in a clear and

readable style. It is therefore a potentially interesting paper for all clinicians involved

in the treatment of these very frequent and often lethal cancers.

Reply: Thanks for your comments.

Below is a point-by-point summary of the changes to the comments of Reviewer 1.

In the hopes of improved readability (Reviewer 1 - Grade B), the manuscript has been

submitted for editing with AJE and new language certificate provided. The suggested

edits have been incorporated into the revised manuscript.

Below is a point-by-point summary of the changes to the comments of Science editor.

1 (4) There are now 45 references. 3 references from Eur J Surg Oncol were removed to

fulfil the requirement of only 3 articles cited from one journal. 1 reference was added

(Campana - recently published) instead of unpublished data (page 15).

5 Issues raised:

(1) The approved grant application form was added to the upload under 69530-Approved Grant Application Form. You can find it on the page 9 of Funding agency contract.

- 1	44	302	LT-0303	VEIIIV	וויוכעונווואס וונוגס	Inonciticial	OT LOT AT EAT OF THE	AT AT CATA AT TE CACT	alasti ie	-	311.02/00
	22	302	P3-0003	Nosilec	Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev	Gregor Serša	0140-41/2020/11	01. 01. 2015-31. 12. 2021	5,85 FTE	C	146.773,57
- 1			02 0200	Martha	212111	AUL I D. TIE	0140 55 (2010/0	01 01 2010 21 12 2024	1 77 575	0	44 257 07

- (2) Original figures were arranged according to the instructions in single PowerPoint file and all elements were tested to be movable and can be reprocessed by the editor.
- (3) Pictures provided were not used before.
- (4) As stated in 1 (4) we fulfilled the request and we removed 3 references out of 6 from Eur J Surg Oncol. We revised the reference list accordingly.

Below is a point-by-point summary of the changes to the comments of Company editor-in-chief.

Figures were arranged according to the instructions in single PowerPoint file and all elements were tested to be movable and editable.